J. Cassidy, D. Bissett, Roy A. J. Spence OBE, M. Payne, G. Morris-Stiff
{"title":"肿瘤外科","authors":"J. Cassidy, D. Bissett, Roy A. J. Spence OBE, M. Payne, G. Morris-Stiff","doi":"10.1093/med/9780199689842.003.0003","DOIUrl":null,"url":null,"abstract":"Cancer is a disease of the genes. In the last two decades new technologies have allowed us to interrogate the genome more efficiently and faster. This has led to new therapies and improved understanding of cancers. It is clear the few cancers are caused by just one gene defect and in these rare cases the defective gene or its product is a target for therapeutic intervention. The bigger challenge now is to use this paradigm against multi-genic cancers which are far more common and more complex in their genetic makeup.","PeriodicalId":19711,"journal":{"name":"Oxford Medicine Online","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Surgical oncology\",\"authors\":\"J. Cassidy, D. Bissett, Roy A. J. Spence OBE, M. Payne, G. Morris-Stiff\",\"doi\":\"10.1093/med/9780199689842.003.0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer is a disease of the genes. In the last two decades new technologies have allowed us to interrogate the genome more efficiently and faster. This has led to new therapies and improved understanding of cancers. It is clear the few cancers are caused by just one gene defect and in these rare cases the defective gene or its product is a target for therapeutic intervention. The bigger challenge now is to use this paradigm against multi-genic cancers which are far more common and more complex in their genetic makeup.\",\"PeriodicalId\":19711,\"journal\":{\"name\":\"Oxford Medicine Online\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oxford Medicine Online\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/med/9780199689842.003.0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxford Medicine Online","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/med/9780199689842.003.0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cancer is a disease of the genes. In the last two decades new technologies have allowed us to interrogate the genome more efficiently and faster. This has led to new therapies and improved understanding of cancers. It is clear the few cancers are caused by just one gene defect and in these rare cases the defective gene or its product is a target for therapeutic intervention. The bigger challenge now is to use this paradigm against multi-genic cancers which are far more common and more complex in their genetic makeup.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
